Cytotoxic activity in the serum of a patient with metastasizing nephroblastoma given intravenous infusions of alkyl-lysophospholipids in a phase I study.
In a phase I study a cytotoxic activity in the serum of a tumor patient given infusions of synthetic alkyl-lysophospholipid has been demonstrated. Serum samples collected after ALP infusions inhibited 3H-thymidine incorporation by human leukemic cells to an extent that correlated to the dose of ALP administered. Serum taken after the highest dose of ALP given (50 mg/kg body weight) led to complete cell destruction after 72 h in vitro. Whereas cells from the HL60 line were very sensitive to the serum cytotoxicity, K562 cells were much less affected. Cytotoxic activity was found to be clear from the circulation in a biphasic manner; more than 50% disappeared within 6-8 h but 20-30% was still present after 4 days.
D000328:Adult; D006801:Humans; D007275:Injections, Intravenous; D007680:Kidney Neoplasms / Q000097:blood / Q000188:drug therapy*; D008246:Lysophospholipids; D008297:Male; D009362:Neoplasm Metastasis; D010743:Phospholipids / Q000008:administration & dosage / Q000627:therapeutic use*; D009396:Wilms Tumor / Q000097:blood / Q000188:drug therapy*
D008246:Lysophospholipids; D010743:Phospholipids